← Leaderboards
Shi-Yong Sun
Emory University
$12,583,440
Attributed
$12,583,440
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,583,440 · 7
By mechanism
R01$10,679,105 · 6
P50$1,904,335 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Chunhai Charlie Hao$5,475,176
- Fadlo Raja Khuri$2,954,298
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCancer Cell LineMolecularCancer CellProteinsGenesMediatingApoptosisPharmaceutical PreparationsMutationResponseMalignant Neoplasm Of LungNon-Small-Cell Lung CarcinomaSignal TransductionIn VivoKnock-DownCell LinePlayFda ApprovedOverexpressionBiologicalTreatment EfficacyDown-RegulationIn Vitro
Grant awards (40)
Targeting PGC1β/PPARγ axis for overcoming acquired resistant to third generation EGFR-TKIs$484,479
R01 · FY2025 · CA · contact PI
Targeting hTERT/telomerase for managing acquired resistance to third generation EGFR-TKIs in lung cancer$437,402
R01 · FY2025 · CA · contact PI
c-Myc modulation and its implications in EGFR-targeted cancer therapy$254,998
R01 · FY2025 · CA · contact PI
Targeting PGC1β/PPARγ axis for overcoming acquired resistant to third generation EGFR-TKIs$474,087
R01 · FY2024 · CA · contact PI
Targeting hTERT/telomerase for managing acquired resistance to third generation EGFR-TKIs in lung cancer$433,505
R01 · FY2024 · CA · contact PI
c-Myc modulation and its implications in EGFR-targeted cancer therapy$388,359
R01 · FY2024 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$422,711
R01 · FY2023 · CA · contact PI
c-Myc modulation and its implications in EGFR-targeted cancer therapy$390,871
R01 · FY2023 · CA · contact PI
c-Myc modulation and its implications in EGFR-targeted cancer therapy$176,401
R01 · FY2022 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$112,991
R01 · FY2022 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$1
R01 · FY2022 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$439,107
R01 · FY2021 · CA · contact PI
c-Myc modulation and its implications in EGFR-targeted cancer therapy$403,092
R01 · FY2021 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$115,235
R01 · FY2021 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$439,107
R01 · FY2020 · CA · contact PI
c-Myc modulation and its implications in EGFR-targeted cancer therapy$399,207
R01 · FY2020 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$404,222
R01 · FY2019 · CA · contact PI
Modulation of death receptor 4 in EGFR-targeted cancer therapy$366,875
R01 · FY2018 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$321,625
R01 · FY2016 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$321,625
R01 · FY2015 · CA · contact PI
Enhancing mTOR-targeted cancer therapy$267,147
R01 · FY2015 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$311,976
R01 · FY2014 · CA · contact PI
Enhancing mTOR-targeted cancer therapy$259,132
R01 · FY2014 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$302,328
R01 · FY2013 · CA · contact PI
Enhancing mTOR-targeted cancer therapy$251,118
R01 · FY2013 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$154,669
R01 · FY2013 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$321,625
R01 · FY2012 · CA · contact PI
Enhancing mTOR-targeted cancer therapy$267,147
R01 · FY2012 · CA · contact PI
Therapeutic potential of mTOR kinase inhibitors in lung cancer$164,541
R01 · FY2012 · CA · contact PI
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCER$364,300
P50 · FY2011 · CA · contact PI
Enhancing mTOR-targeted cancer therapy$267,147
R01 · FY2011 · CA · contact PI
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCER$410,808
P50 · FY2010 · CA · contact PI
Enhancing the mTOR-targeted cancer therapy$263,700
R01 · FY2010 · CA · contact PI
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCER$400,730
P50 · FY2009 · CA · contact PI
Enhancing the mTOR-targeted cancer therapy$263,700
R01 · FY2009 · CA · contact PI
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCER$397,483
P50 · FY2008 · CA · contact PI
Enhancing the mTOR-targeted cancer therapy$263,700
R01 · FY2008 · CA · contact PI
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCER$331,014
P50 · FY2007 · CA · contact PI
Enhancing the mTOR-targeted cancer therapy$263,700
R01 · FY2007 · CA · contact PI
Enhancing the mTOR-targeted cancer therapy$271,575
R01 · FY2006 · CA · contact PI